O
Olli Kallioniemi
Researcher at University of Helsinki
Publications - 376
Citations - 44711
Olli Kallioniemi is an academic researcher from University of Helsinki. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 90, co-authored 353 publications receiving 42021 citations. Previous affiliations of Olli Kallioniemi include European Bioinformatics Institute & Åbo Akademi University.
Papers
More filters
Journal ArticleDOI
Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms.
Sara Kangaspeska,Susanne Hultsch,Henrik Edgren,Daniel Nicorici,Astrid Murumägi,Olli Kallioniemi +5 more
TL;DR: In this article, the authors demonstrate the importance of continuous optimization of the bioinformatic methodology for this purpose, and report the discovery and experimental validation of 13 additional fusion genes from the same samples.
Journal ArticleDOI
Functional evidence implicating S100P in prostate cancer progression
Gargi D. Basu,David O. Azorsa,Jeff Kiefer,Angela M. Rojas,Sukru Tuzmen,Michael T. Barrett,Jeffrey M. Trent,Olli Kallioniemi,Spyro Mousses +8 more
TL;DR: These results provide the first functional proof that S100P overexpression can upregulate androgen receptor expression and thereby promote prostate cancer progression by increasing cell growth and suggest that the protein may directly confer resistance to chemotherapy.
Patent
Specific inhibition of gene expression by small double stranded rnas
Natasha J. Caplen,Richard A. Morgan,Andrew Fire,Susan Parrish,Spyro Mousses,Olli Kallioniemi,J. Robert Cornelison,Eric W.F.W. Alton,Uta Griesenbach +8 more
TL;DR: Synthetic small double stranded RNAs that can induce gene specific inhibition of expression are provided, as well as methods for selecting and constructing optimal small double-stranded RNAs as discussed by the authors.
Journal ArticleDOI
Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model
E. Hyytinen,G. N. Thalmann,H. E. Zhau,Ritva Karhu,Olli Kallioniemi,Leland W. K. Chung,Tapio Visakorpi +6 more
TL;DR: An accumulation of genetic changes correlates with tumour progression in this experimental in vivo model of prostate cancer progression, and it is possible that the specific chromosomal aberrations involved in this model system may provide clues to the location of genes involved in human prostate cancers progression and metastasis.
Journal ArticleDOI
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Emma I. Andersson,S. Pützer,Bhagwan Yadav,Olli Dufva,Sofia Khan,Liye He,Leopold Sellner,Leopold Sellner,Alexandra Schrader,Giuliano Crispatzu,Małgorzata Oleś,Henan Zhang,Shady Adnan-Awad,Sonja Lagström,Dorine Bellanger,J P Mpindi,Samuli Eldfors,Tea Pemovska,Paavo Pietarinen,Anneli Lauhio,Katarzyna Tomska,Katarzyna Tomska,Carlos Cuesta-Mateos,Edgar Faber,Steffen Koschmieder,T H Brümmendorf,Soili Kytölä,Eeva-Riitta Savolainen,Timo Siitonen,Pekka Ellonen,Olli Kallioniemi,Krister Wennerberg,Wei Ding,Marc-Henri Stern,Wolfgang Huber,Simon Anders,Jing Tang,Jing Tang,Tero Aittokallio,Tero Aittokallio,Thorsten Zenz,Thorsten Zenz,Marco Herling,Satu Mustjoki +43 more
TL;DR: It is found that genetic markers do not readily translate into novel effective therapeutic vulnerabilities, and novel classes of compounds with high efficacy in T-PLL were discovered with the comprehensive ex vivo drug screening platform warranting further studies of synergisms and clinical testing.